Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial.

By R. Green, C. Brightling, S. Mckenna, B. Hargadon, D. Parker, P. Bradding, A. Wardlaw, I. Pavord. The Lancet, 2002

1,767 citations recorded by the source corpus.

Subfields: Physiology, Pulmonary and Respiratory Medicine, Sociology and Political Science

View Paper: https://www.semanticscholar.org/paper/f05cae79f33fd83b4a1a1f9a39d57bc03f4090d4

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Physiology

1. Sally E. Wenzel
2. Marc E. Rothenberg
3. Ian M. Adcock
4. P. Barnes

In Pulmonary and Respiratory Medicine

1. Sally E. Wenzel
2. P. Barnes

In Sociology and Political Science

1. Sally E. Wenzel

Citations in the corpus

• Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma (2009, neutral): “Nasal polypectomy (elective) 0 1 (3) Musculoskeletal pain 1 (3) 2 ( 6 )”
• Eosinophils: Biological Properties and Role in Health and Disease (2008, background): “In fact a management strategy directed at normalizing the sputum eosinophil count was more effective than traditional management strategy (based on lung function, assessment of symptoms, and use of rescue b2 agonists) in reducing the number of asthma exacerbations (Green et al. 2002).”
• International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma (2013, methodology): “This review included three randomized controlled trials in adults [182, 249, 250].”